secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2025-09-11T23:59:59+00:00
Accession:  0001178913-25-003292
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion reports preclinical data showing SIL204 reaches metastatic sites in pancreatic cancer model
--------------------------------------------------------------------------------

- Subcutaneous SIL204 (5 mg/mouse) distributed to liver, peritoneum, lung in Panc-1 KRAS G12D metastatic model.
- Tumor burden reduced significantly (p<0.01) in peritoneum, lung, intestine; liver showed measurable reduction.
- Data supports dual-route strategy: intratumoral for primary tumor, systemic for metastases.
- Phase 2/3 trial on track for H1 2026; regulatory submissions planned Q4 2025 and Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325003292/0001178913-25-003292-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325003292/zk2533776.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-003292

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer